NASDAQ:IMMP
Immutep Ltd Stock News
$2.96
+0.0400 (+1.37%)
At Close: May 17, 2024
Media Release No safety or tolerability issues in open-label, safety lead-in phase evaluating the higher 90mg dose of efti in combination with weekly paclitaxel in the first 6 patients Good safety pro
Immutep Announces New Biomarker Data from TACTI-002 Phase II in First Line Non-Small Cell Lung Cancer
12:00pm, Friday, 03'rd Nov 2023
Media Release Statistically significant increases of Th1 biomarkers (IFN-gamma, CXCL-10), circulating immune cells (lymphocytes), and RNA levels of immune activating genes were observed and linked to
Immutep to Participate in November Investor Events
08:00am, Thursday, 02'nd Nov 2023
SYDNEY, AUSTRALIA, Nov. 02, 2023 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a clinical-stage biotechnology company developing novel LAG-3 immunoth
Immutep Quarterly Activities Report Q1 FY24
08:00am, Tuesday, 31'st Oct 2023
Media Release Excellent survival benefit in 1st line non-small cell lung cancer (1L NSCLC) in TACTI-002 trial: median Overall Survival of 35.5 months (TPS ≥1% patients) providing additional 12-18 mo
Immutep receives ~A$1.13 million R&D Tax Incentive
08:00am, Wednesday, 25'th Oct 2023
Media Release (Code: ASX: IMM; NASDAQ: IMMP) SYDNEY, AUSTRALIA, Oct. 25, 2023 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or the “Company”), is pleased to announce
Immutep to Participate in September Investor Conferences
09:00am, Tuesday, 05'th Sep 2023
SYDNEY, AUSTRALIA, Sept. 05, 2023 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a clinical-stage biotechnology company developing novel LAG-3 immunot
Immutep: Nipping At The Heels Of LAG3.Is It Impressive Enough?
06:57pm, Friday, 01'st Sep 2023
Immutep Limited is a small cap biotech focusing on the development of eftilagimod alpha, a novel molecule that activates MHC class II molecules to enhance the immune response. The company is conductin
7 Stocks That Could Triple Your Money by 2024
09:09pm, Wednesday, 09'th Aug 2023
Stocks to triple your money isn't an ideal approach for everyone, if I may be blunt. Before you engage in wild speculation, you want to have your financial bases covered.
Immutep price target suggests stock has much further to go
09:38am, Monday, 07'th Aug 2023
Baird, the investment bank, has initiated coverage on Immutep Ltd (ASX:IMM) (IMMP), a clinical-stage biotechnology company, with an "outperform" rating and a price target of $7 - a significant premiu
3 Best Penny Stocks Under $3 to Buy in June
07:01pm, Wednesday, 14'th Jun 2023
While the idea of acquiring the best penny stocks under $3 may appeal to your inner contrarian, you need to first understand the risks. In most cases, shares that trade this low do so for a reason, an
Immutep (IMMP) Up on Initial Data From Lung Cancer Study
04:17pm, Thursday, 25'th May 2023
Immutep (IMMP) shares surge on encouraging initial data from a triple combination therapy study, INSIGHT-003, for non-small cell lung cancer.
Immutep (IMMP) Surges 65% on Upbeat Lung Cancer Study Data
01:48pm, Thursday, 18'th May 2023
A mid-stage study data shows that Immutep's (IMMP) lead candidate as a combination therapy in first-line NSCLC achieved better-than-expected overall survival results.
3 Advanced Penny Stocks Trading Techniques
06:00am, Thursday, 18'th May 2023
Use these advanced penny stocks trading techniques as part of your strategy The post 3 Advanced Penny Stocks Trading Techniques appeared first on Penny Stocks to Buy, Picks, News and Information | P
7 Best Penny Stocks Under $3 to Buy in April
07:55pm, Wednesday, 12'th Apr 2023
There are speculative ideas and then there are the best penny stocks under $3. And don't be fooled by the word “best.
Why Did Immutep Ltd Stock Soar Recently?
02:01am, Wednesday, 28'th Dec 2022
Analysts and investors alike appear enamored with Immutep Ltd, whose earnings are growing; more of which could come from their latest product candidate.